Abstract: The present invention relates to a novel topical composition for treatment of the skin. The composition is a microemulsion that comprises curcumin or a curcumin derivative. The composition is able to penetrate into skin cells where it induces the production of adenosine triphosphate (ATP) and promotes the formation of new skin cells. The formation of new skin cells smoothes the skin and alleviates lines and wrinkles. The topical composition can be applied to the skin of a person daily. The invention also relates to the use of the novel topical composition for delaying skin aging. In another aspect, the invention relates to the use of the novel composition for reducing or preventing hair loss and/or inducing the growth of new hair.

Abstract: The invention describes a core shell microcapsule wherein the capsule shell is hydrolysable.

Abstract: A stable and consistent reversible coloured photochromic additive changes colour from original buff to desired colour shade between pink to blue when exposed to sunlight and restores to original colour in the absence of the sunlight; simultaneously having synergistic SPF value of at least 3. The additive comprises titanium dioxide, psuedoboehmite, iron oxide hydroxide and tungsten oxide.

Abstract: The present invention belongs to the field of medicaments and daily chemicals, and relates to use of cannabidiol or an cannabis extract in preparing a skin whitening product. Particularly, the present invention relates to use of any one of (1) to (2) below in preparing a drug or a reagent for inhibiting tyrosinase activity, inhibiting melanin formation or inhibiting melanocyte generation: (1) cannabidiol or a pharmaceutically acceptable salt or ester thereof; and (2) a plant extract containing cannabidiol. The cannabidiol or the cannabis extract can effectively inhibit activity of tyrosinase, and has a good skin whitening effect.

Abstract: The present invention relates to a cosmetic composition having a monophasic appearance, comprising at least one particular non-ionic surfactant, water and at least one propellant. The invention also relates to an aerosol device and also to a process for styling keratin fibres using such a composition.

Abstract: A topically applicable chemical peel composition for home use having from about 4% to about 13%, by weight, of alpha hydroxy acid, from about 0.1% to about 2.0%, by weight, of salicylic acid, from about 0.1% to about 2.0%, by weight, of phenylethyl resorcinol and balance essentially dermatologically acceptable liquid solvent comprising water and ethanol, the ethanol present from about 10 to about 90 wt %. In addition, a chemical skin peel regime or regimen including topical application onto the skin is also disclosed.

Abstract: A method for strengthening and repairing keratin fibres including providing a first—and a second crosslinking composition, wherein the first—crosslinking composition comprises an at least bi-functional Brønsted-base and the second—crosslinking composition comprises—an at least bi-functional organic acid, and a cosmetically acceptable carrier; applying the first—as well as the second—crosslinking composition to keratin fibres; and optionally mixing the first—crosslinking composition into a commercially available hair coloring or hair bleaching composition.

Abstract: The present disclosure relates to a hair treatment agent comprising at least one specific chelating agent, at least one diol and at least one triol. Moreover, the present disclosure relates to the use of the specific chelating agent to remove undesired multivalent metal ions from hair that has previously been treated with relaxing agents containing at least one multivalent metal ion. Furthermore, the present disclosure relates to a method for relaxing keratinic fibers wherein the inventive hair treatment agent is applied after relaxing the hair with a relaxing composition comprising a multivalent metal hydroxide. After the inventive hair treatment agent is applied, the hair is treated with an acidic cleansing composition. Finally, the present disclosure relates to a kit of parts, comprising a hair relaxing composition with a multivalent metal hydroxide, an inventive hair treatment composition and an acidic cleansing composition in separate containers.

Abstract: The present invention is in the field of hair treatment compositions; in particular relates to hair treatment compositions for hair volume reduction. Despite the prior art, there still exists the opportunity to increase the conditioning benefits delivered through hair treatment compositions. It is therefore an object of the present invention to provide a hair treatment composition that retains shape and reduces frizz even after exposure to humidity and washing the hair. It has been found that reduced hair frizz and hair shape retention even after exposure to moisture can be obtained by using N-formyl amino acids.

Abstract: The present invention relates to a topical composition comprising from 0.001 to 10% by weight a compound of formula (I), i.e. N-cyclopropyl nicotinamide, that provides improved antimicrobial effect through generation of antimicrobial peptides when applied to an external surface of the human body. A combination of compound of formula I and at least one ingredient selected from niacinamide, picolinamide and iso-nicotinamide triggers generation of AMPs in a synergistic way.

Abstract: The present invention relates to a skin depigmentation composition comprising (i) at least one thiophosphate derivative and (ii) acceptable carriers for topical, oral and/or parenteral administrations to human. The present invention further relates to the cosmetic and medical treatment uses thereof for reducing skin and/or hair pigmentation.

Abstract: Provided is a novel peptide and a cosmetic composition for inhibiting a skin-aging or a skin-wrinkle formation including the same. The peptide has activities for facilitating the bindings between keratinocytes; and increasing the expressions of junction proteins significantly.

Abstract: Methods and kids for removing calculus from a tooth. The method can include applying a component A comprising a hydrogen peroxide or a precursor thereto and a component B the comprising a catalase to the tooth, thereby generating oxygen; and removing at least a part of the calculus from the tooth.

Abstract: Provided herein is a method of at least partly removing a biological deposit, such as a dag, from the skin of an animal. The method includes administering to the biological deposit an effective amount of a composition containing a keratinase, and optionally one or both of a reducing agent and a surfactant. Also provided is a composition for use in the aforementioned method as well as a method of making same.

Abstract: The present invention relates to a composition, especially a cosmetic, in particular photoprotective, composition, comprising at least: —one or more particular acrylic polymers —one or more fatty acid esters of dextrin, and —one or more UV-screening agents.

Abstract: An actinic light curable dip gel comprises an acrylic resin selected from the group consisting of a poly(C1-12alkyl(meth)acrylate) polymer, an acrylate functional acrylic resin, and mixtures thereof; a monomer; at least one photoinitiator; and a solvent. A layer of this actinic light curable dip gel is applied onto a nail, followed by an application of a polymer powder onto the nail; and exposing the nail to actinic light. The steps of applying the gel layer and the polymer powder may be repeated several times prior to exposing the nail to actinic light. The use of the actinic light curable dip gel has several advantages over the traditional dip system.

Abstract: An anhydrous and alcohol-free slow fragrance diffusive composition (lotion, gel or cream) with longer lasting properties than hydroalcoholic formula fragrance product that contains 50 to 75 percent by weight dimethicone crosspolymer gel, 0.01 to 30 percent by weight fragrance oil and 5 to 40 percent by weight volatile linear silicone fluid. Emollients may be added to moisturize the skin, improve the fragrance rendition and/or increase the miscibility of the fragrance oil in the composition when a high level of dimethicone is used (in case of a lotion for example). Moreover, a preservative and some pigments can be added to the formula to preserve the fragrant product from bacteria contamination and to improve the aesthetics respectively.

Abstract: Disclosed herein are liquid cleansing compositions comprising a foam booster comprising ethoxylated hydrogenated castor oil present in an amount ranging from about 0.5% to about 2% based on the total weight of the composition, castor oil maleate, glycerin, and at least one surfactant, wherein the pH of the composition is less than about 7. The liquid cleansing compositions disclosed herein provide enhanced foam volume and texture. Further disclosed herein are methods of making a liquid cleansing composition.

Abstract: The present invention relates to an ear-cleansing agent for companion animals and a method of manufacturing the same. More particularly, the present invention relates to an ear-cleansing agent for companion animals, which includes distilled Chamaecyparis obtusa water extracted from Chamaecyparis obtusa trees so as to enable antibacterial action, deodorization, and exfoliation and which does not include a surfactant so that the skin is not irritated even when the ear-cleansing agent is not washed away using water, and a method of manufacturing the same.

Abstract: The disclosure provides compositions and methods for promoting hair growth and reducing hair loss using bioactive extracts of curcumin, Withania somnifera, and saw palmetto.

Abstract: The present invention relates to compositions for modulating genes responsible for the general functions of the skin comprising at least one plant extract and at least one cosmetically acceptable vehicle, as well as to a method for modulating the expression of genes responsible for the general functions of the skin, and use of said plant extract in the preparation of a composition for modulating genes responsible for the general functions of the skin.

Abstract: Disclosed in the specification is a skin whitening composition comprising as an effective ingredient a Pseudoalteromonas carrageenovora strain, a lysate thereof, a culture thereof, or an extract from the strain, lysate, or culture. Also, the specification discloses a Pseudoalteromonas carrageenovora SNC 121 strain, deposited with accession number KCCM12049P, which exhibits a skin whitening function.

Abstract: The invention provides a probiotic formulation that includes an LDH-deficient nutans streptococcus strain and an attenuated S. oralis strain. S. uberis strains can be included in the probiotic formulation.

Abstract: A method and system to prevent sore throat infections in humans includes the administration of an active ingredient to a site on the mucus membranes of the throat of a human that inhibits adherence and promotes desorption of S. pyogenes to soft tissue surfaces, such as the pharyngeal and oral mucosa of a human. A mucoadhesive strip having a surface topography that resists bioadhesion of undesired bacteria that are typically present in a human's mouth is preferably employed and that has one or more encapsulated agents selected from the group consisting of an antibiotic; lactic acid bacteria; S. pyogenes modified by a CRISPR-Cas system to reduce one or more virulence factors; and a breath mint solution.

Abstract: The present disclosure provides topical skin formulations including sunscreen compositions and cannabidiol compositions. The present disclosure further provides topical skin formulations including both sunscreen agents and cannabidiol. The sunscreen agents are included in an amount from about 0.01 to 20% by weight. Cannabidiol is included in an amount from about 0.01 to 10% by weight. A method for applying multiple topical skin formulations includes separately storing a sunscreen composition and a cannabidiol composition in a multi-chambered device. The multi-chambered device may be configured to dispense each composition independently of the other or simultaneously in adjustable ratios.

Abstract: Pre-filled syringes, pharmaceutical compositions, and kits and methods relating to same allow for emergency administration of one or more drugs from prefilled glass syringes to a patient via a needleless connector. In preferred embodiments, the prefilled glass syringe has a drug volume of at least 5 mL, has a Luer-lock, and has a syringe tip with an internal channel that has a diameter of about 1.7 mm. Such syringes advantageously allow storage of emergency drugs without leaching of plastic materials and degradation, and substantially improve the safety profile where the syringe is attached to an IV line via a needleless connector.

Abstract: A biocompatible antimicrobial composition effective against microbial biofilms, including in vivo biofilms containing gram-positive bacteria, can be delivered to and used near the spinal column of vertebrates. Once introduced to an area colonized with a bacterial biofilm, particularly an intervertebral disc, the antimicrobial composition weakens the EPS/ECPS macromolecules of the biofilm, which makes the entire biofilm structure susceptible to being dislodged from the affected area or biosorbed. Additionally or alternatively, certain of the subcomponents of the solute component, as well as perhaps the organic liquid(s) of the solvent component, might lyse microbes, particularly gram-positive bacteria, previously protected by the EPS/ECPS macromolecules. Swelling of and around previously impacted intervertebral discs can be reduced or eliminated, often resulting in appreciable reductions in patient pain levels.

Abstract: The present disclosure relates to compositions, including, hydrogel compositions useful as analgesics including cannabinoids, menthol and anesthetic in a composition formulated to be administrable to a non-human animal rectally as a suppository. The menthol component can be a stabilized menthol composition comprising menthol and at least one menthol stabilizer compound including undecylenic acid methyl ester, undecylenic acid or a salt of undecylenic acid.

Abstract: The present invention includes pourable, non-toxic lubricating compositions containing carrageenan and more precisely ? carrageenan as an anti-viral agent, for protection from Human Papillomavirus (HPV), and methods of using the lubricating compositions as a non-oily, pseudoplastic lubrication product and administering the carrageenan for reducing the propagation of HPV during sexual activity.

Abstract: The present invention includes pourable, non-toxic lubricating compositions containing carrageenan and more precisely ? carrageenan as an anti-viral agent, for protection from Human Papillomavirus (HPV), and methods of using the lubricating compositions as a non-oily, psuedoplastic lubrication product and administering the carrageenan for reducing the propagation of HPV during sexual activity.

Abstract: A biocompatible intravaginal device adapted for the delivery of therapeutic active ingredients (agents) is provided. The device is constructed to be insertable and remain in the vagina for up to a month (28 to 31 days) or more. The device is loaded with the active agents prior to insertion and constructed to continuously release a therapeutically effective amount of the agents during the duration of up to a one month insertion. Preferred agents include contraceptive and anti-infection agents. It is preferred that the agents are non-hormonal.

Abstract: Multilayer thin film devices that include a bioactive agent for elution to the surrounding tissue upon administration to a subject are provided. The multilayer thin film devices are useful as medical devices, such as ocular devices. Also provided are methods and kits for localized delivery of a bioactive agent to a tissue of a subject, and methods of preparing the subject devices. The multilayer thin film medical device includes a first layer, a bioactive agent and a second layer. The first and the second layers may be porous or non-porous. The devices have a furled structure, suitable for administration to a subject.

Abstract: Provided is an oral pharmaceutical composition characterized by containing a medicinal ingredient (A), a hydrophobic liquid (B), a water-soluble macromolecular substance (C), and an excipient (D), but not containing a surfactant, wherein: the medicinal ingredient (A) is included in the hydrophobic liquid (B); and the hydrophobic liquid (B) is dispersed in a composition including the water-soluble macromolecular substance (C) and the excipient (D). The oral pharmaceutical composition: allows easy dose-adjustment; has excellent dosability and safety; is biologically equivalent to a standard formulation having established profiles regarding efficacy, safety, etc.; and can be easily produced.

Abstract: The present invention relates, in various embodiments, to formulations comprising hydrocortisone and silicon dioxide. In additional embodiments, the invention relates to suppositories comprising hydrocortisone and silicon dioxide. The formulations of the present invention are useful for administration to patients who have gastrointestinal diseases and disorders such as, for example, inflammatory bowel disease.

Abstract: The present invention relates to a novel preparation. The present invention has an advantage of enabling bitterness of the raw material medicine to be masked by only the physical shape thereof. The present invention breaks away from general knowledge, and is a concept having never been conceived of thus far and is a novel preparation, which can be widely used in the pharmaceutical industry in the future.

Abstract: The disclosure provides a stable nanoemulsion concentrate suitable for formulation of one or more non-polar active ingredients, for example a cannabinoid, together with methods of making and using the same.

Abstract: A composition and method for treating a subject following myocardial infarction are provided. The composition includes a non-PEGylated liposome. The method includes administering a non-PEGylated liposome to a subject in need thereof following myocardial infarction.

Abstract: The invention features methods and apparatus for producing lipid nanoparticles. Methods of the invention include injecting a lipid solution into an aqueous solution at an automated rate (e.g., a rate controlled by a servo pump). The invention provides methods and apparatus for making lipid nanoparticles possessing a wide range of lipid components and hydrophilic encapsulants, including nucleic acids (e.g., mRNA). Also provided are nanoparticles and compositions thereof made by methods and apparatus of the invention.

Abstract: The present invention provides a method for producing a pharmaceutical composition containing fine particles of a poorly soluble drug, comprising mixing a sugar or a sugar alcohol with a dispersion of nanoparticles of the poorly soluble drug and granulating the obtained mixture.

Abstract: The present invention relates to pharmaceutical compositions comprising safinamide and, more particularly, to taste-masked particles comprising said active ingredient or pharmaceutically acceptable salts thereof, oral dosage forms that include said particles and a process for preparing them.

Abstract: The present invention relates to a tablet comprising one or more omega-3 fatty acid amino acid salt(s), a method for preparing a tablet according to the invention and the use of a tablet according to the invention as a food supplement or as a pharmaceutical product.

Abstract: The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner.

Abstract: The present disclosure relates to formulations, such as tablets, of FXR agonists and therapeutic uses thereof. The disclosure also relates to methods for obtaining such formulations.

Abstract: A method of preparing a pharmaceutical product comprises the steps of (a) providing a neat active pharmaceutical ingredient (API) complying with at least five of the following parameters determined by using a FT4 powder rheometer: (i) specific basic flow energy of at most 60 mJ/g; (ii) stability index of 0.75 to 1.25; (iii) specific energy of at most 10 mJ/g; (iv) major principle stress at 15 kPa of at most 40; (v) flow function at 15 kPa of at least 1.3; (vi) consolidated bulk density at 15 kPa of at least 0.26 g/mL; (vii) compressibility of at most 47%; and (viii) wall friction angle of at most 40°; (b) dispensing the neat API of step (a) into a bottom part of a pharmaceutical carrier using a vacuum assisted metering and filling device; and (c) encapsulating the bottom part, thereby producing a pharmaceutical product.

Abstract: An application of an oral pharmaceutical composition in manufacturing of a medication for regulating fibroblast growth and treating or preventing organ fibrosis. The pharmaceutical composition comprises a homogeneous mixture of an edible oil, beeswax, and ?-sitosterol, wherein the beeswax forms microcrystals, and on the basis of the total weight of the composition, the content of the beeswax is 0.5-50% and the content of ?-sitosterol is 0.1%-20%.

Abstract: According to one embodiment, a core-shell microsphere includes a polyorganosiloxane shell, and a core inside the shell, the core having a carrier and at least one component, where the at least one component is configured to be released post processing. In addition, an average diameter of the polyorganosiloxane shell is in a range of greater than about 1 micron to less than about 100 microns.

Abstract: This invention provides methods for the formation of biocompatible membranes around biological materials using photopolymerization of water soluble molecules. The membranes can be used as a covering to encapsulate biological materials or biomedical devices, as a “glue” to cause more than one biological substance to adhere together, or as carriers for biologically active species. Several methods for forming these membranes are provided. Each of these methods utilizes a polymerization system containing water-soluble macromers, species, which are at once polymers and macromolecules capable of further polymerization. The macromers are polymerized using a photoinitiator (such as a dye), optionally a cocatalyst, optionally an accelerator, and radiation in the form of visible or long wavelength UV light. The reaction occurs either by suspension polymerization or by interfacial polymerization.

Abstract: There are provided an enteric coating composition having an excellent film-forming property, being capable of forming a film at a lower temperature than conventional compositions, and/or being capable of avoiding decomposition of a drug due to a high temperature and operational troubles due to or nozzle clogging; and others. More specifically, there are provided an enteric coating composition containing hypromellose acetate succinate having a molar substitution of hydroxypropoxy groups of 0.40 or more, and water; a method for producing a solid preparation including steps of coating a drug-containing core with the enteric coating composition to obtain a coating layer, and drying the coating layer; and a solid preparation containing a drug-containing core, and a coating layer directly or indirectly on the core, the coating layer containing a hypromellose acetate succinate having a molar substitution of hydroxypropoxy groups of 0.40 or more.

Abstract: A controlled-release multilayer microparticle containing a pharmaceutically active compound, which is intended for oral administration or direct administration in the stomach, which may be done using a liquid pharmaceutical composition containing the microparticle. The microparticle may include: a core that includes the pharmaceutically active compound, which may be pramipexole; a controlled-release intermediate coating layer; and an outmost external protection coating layer surrounding the controlled-release intermediate coating layer. The external protection coating layer may include a mixture of: a hydrophilic gastro-soluble component which is insoluble in aqueous media at a pH of between 6.5 and 7.5; and a hydrophobic and/or insoluble component.

Abstract: Methods are provided for coating particles characterised by the addition of a powdered excipient, typically during coating. Typically, the coating method comprises Wurster fluidized bed coating. The method provides for coating particles in a coater comprising a coating processing chamber, wherein the particles comprise an active pharmaceutical ingredient. The coated particles are preferably for use in a method of administering an active pharmaceutical ingredient or for use in a method of treating or preventing a disease or condition. The invention further provides a pharmaceutical composition comprising coated particles obtainable by the method of the invention, preferably as part of a liquid formulation for oral administration.